Used in targeted cancer therapies, particularly for solid tumors such as lung, colon, and ovarian cancers. Binds specifically to CDCP1 (CD318), a cell surface protein overexpressed in tumor cells and cancer stem cells, enabling targeted delivery of therapeutic agents or immune-mediated destruction. Employed in antibody-drug conjugates (ADCs), CAR-T cell development, and diagnostic imaging to identify and monitor CDCP1-positive malignancies. Also utilized in research to study tumor progression, metastasis, and cancer cell signaling pathways. Shows potential in blocking CDCP1-mediated survival signals, thereby enhancing the efficacy of chemotherapy and reducing tumor recurrence.